

Rev03
Update: Dec,14,2021

DATASHEET

IFN- γ R II, Human

Cat. No.: Z03135

Product Introduction

Species	Human
Protein Construction	IFN- γ R II (Ser28-Gln247) Accession # P38484
Purity	> 95% as analyzed by SDS-PAGE
Endotoxin Level	< 0.2 EU/ μ g of protein by gel clotting method
Biological Activity	ED ₅₀ < 0.1 μ g/ml, measured in a cell cytotoxicity assay using HT-29 (HTB-38) cells in the presence of 1.0 ng/ml human IFN-gamma.
Expression System	CHO
Apparent Molecular Weight	38~40 kDa, on SDS-PAGE under reducing conditions.
Formulation	Lyophilized after extensive dialysis against PBS.
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O or PBS up to 100 μ g/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

Background

Target Background : IFN-gamma Receptor II, also known as IFNGR2 and IFNGT1, is a transmembrane protein belonging to the type II cytokine receptor family. IFNGR2 is a non-ligand-binding beta chain of the IFN-gamma receptor. It is an integral part of the IFN-gamma signaling transduction pathway and is likely to interact with GAF, JAK1 and JAK2. Defects in IFNGR2 are a cause of autosomal recessive Mendelian susceptibility to mycobacterial disease (MSMD), also known as familial disseminated atypical mycobacterial infection.

Synonyms : IFNGR2; IFNGT1

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.